Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide
Authors:
Open Access
- 1 April 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 108 (4) , 1117-1124
Abstract
The kinetics and metabolism of milacemide have been studied in an animal model which allows the simultaneous investigation of the temporal inter‐relationships of drugs and metabolites in blood (pharmacokinetics) and cerebrospinal fluid (CSF, neuropharmacokinetics) in individual freely moving rats. Milacemide dose‐dependently increased CSF glycine and glycinamide (intermediary metabolite) concentrations. This confirms that milacemide is a CNS glycine prodrug. Pretreatment withl‐deprenyl (2 mg kg−1), a specific inhibitor of monoamine oxidase type B (MAO‐B), almost completely prevented the formation of glycinamide and increased milacemide accumulation in CSF.Tmaxandt1/2were significantly increased andCmaxand AUC values were decreased for glycinamide compared to controls. Pretreatment with clorgyline (5 mg kg−1), a specific inhibitor of MAO‐type A, only moderately decreased glycinamideCmaxand AUC values. After milacemide administration (100, 200 and 400 mg kg−1, i.p.) serum and CSF milacemide concentrations rose linearly and dose‐dependently. Serum glycinamide concentrations exhibited small dose‐dependent rises but these were not linearly related. In contrast, CSF glycinamide concentrations rose linearly and dose‐dependently withCmaxvalues 2.5, 3.2 and 4.1 times greater than the corresponding values for serum glycinamide after giving 100, 200 and 400 mg kg−1respectively of milacemide. Serum glycine concentrations were unaffected but CSF concentrations increased dose‐dependently and these were significant at the higher milacemide doses (200 and 400 mg kg−1). Animals given 400 mg kg−1milacemide had glycine values which were still significantly elevated 7 h later. In conclusion, serum milacemide rapidly enters and equilibrates with the CNS compartment where it is metabolised primarily by MAO‐B to glycinamide and finally to glycine. Metabolism in the peripheral compartment is negligible.Keywords
This publication has 43 references indexed in Scilit:
- Glutamatergic Therapy of Huntingtonʼs ChoreaClinical Neuropharmacology, 1992
- A therapeutic trial of milacemide in myoclonus and the stiff‐person syndromeMovement Disorders, 1991
- The Novel Neuropsychotropic Agent Milacemide Is a Specific Enzyme‐Activated Inhibitor of Brain Monoamine Oxidase BJournal of Neurochemistry, 1989
- Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluidNeuropharmacology, 1988
- Excitotoxity and the NMDA receptorTrends in Neurosciences, 1987
- Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigationsArchives of Gerontology and Geriatrics, 1986
- Double‐Blind Study of Milacemide in Hospitalized Therapy‐Resistant Patients With EpilepsyEpilepsia, 1986
- Conversion of orally administered 2-n.pentylaminoacetamide into glycinamide and glycine in the rat brainLife Sciences, 1983
- EVIDENCE FOR SEPARATE SYSTEMS FOR THE TRANSPORT OF NEUTRAL AND BASIC AMINO ACIDS ACROSS THE BLOOD‐BRAIN BARRIERJournal of Neurochemistry, 1971
- The distribution of glycine in cat spinal cord and rootsLife Sciences, 1965